title: [Use of generic high dose buprenorphine (HDB): about a qualitative survey].
abstract: OBJECTIVE
  Analyze the factors of the low use of buprenorphine (HDB) generic in France, studying heath care professionals' and patients' attitudes towards this substitution.
  
  
  METHODS
  A qualitative method based on the realization of semi-directive conversations was held. 14 health care professionals and 10 patients were interviewed.
  
  
  RESULTS
  Generic drug of HDB presents undeniable economic benefits and galenic advantages. Physicians suggest this generic at first prescription or with stabilized patients. The switch princeps/generic is more difficult with patients who diverted the product, or when they are accustomed to the brand product. Some patients prefer brand product because of its galenics, or of the perception of greater efficiency.
  
  
  CONCLUSIONS
  There is a certain distrust compared to this generic. It is necessary to properly support the prescription of this drug in order to help health care professionals and patients (therapeutic education, medical information, creating a climate of trust).
authors.affiliation: Centre d'évaluation et d'information sur la pharmacodépendance-addictovigilance de Marseille, Pharmacologie clinique, Hôpital Timone, Marseille, France - Institut des neurosciences cognitives de la Méditerranée UMR 6193 CNRS-Aix Marseille Université, Marseille, France.
authors.forename: Yohan
authors.initials: Y
authors.lastname: El-Haïk
authors.affiliation: Centre d'évaluation et d'information sur la pharmacodépendance-addictovigilance de Marseille, Pharmacologie clinique, Hôpital Timone, Marseille, France - Institut des neurosciences cognitives de la Méditerranée UMR 6193 CNRS-Aix Marseille Université, Marseille, France.
authors.forename: Elisabeth
authors.initials: E
authors.lastname: Frauger
authors.affiliation: Centre d'évaluation et d'information sur la pharmacodépendance-addictovigilance de Marseille, Centre associé, Laboratoire de santé publique, EA 3279, Faculté de médecine, Aix Marseille Université, Marseille, France.
authors.forename: Nicolas
authors.initials: N
authors.lastname: Tanti-Hardouin
authors.affiliation: Centre d'évaluation et d'information sur la pharmacodépendance-addictovigilance de Marseille, Pharmacologie clinique, Hôpital Timone, Marseille, France - Institut des neurosciences cognitives de la Méditerranée UMR 6193 CNRS-Aix Marseille Université, Marseille, France.
authors.forename: Joëlle
authors.initials: J
authors.lastname: Micallef
authors.affiliation: Institut des neurosciences cognitives de la Méditerranée UMR 6193 CNRS-Aix Marseille Université, Marseille, France.
authors.forename: Xavier
authors.initials: X
authors.lastname: Thirion
mesh_terms: D000328:Adult; D000701:Analgesics, Opioid / Q000008:administration & dosage / Q000627:therapeutic use*; D001291:Attitude of Health Personnel; D002047:Buprenorphine / Q000008:administration & dosage / Q000627:therapeutic use*; D003625:Data Collection; D004305:Dose-Response Relationship, Drug; D016568:Drugs, Generic / Q000008:administration & dosage / Q000627:therapeutic use*; D005260:Female; D005602:France; D006801:Humans; D008297:Male; D008875:Middle Aged; D010342:Patient Acceptance of Health Care; D010820:Physicians / Q000706:statistics & numerical data; D010818:Practice Patterns, Physicians' / Q000706:statistics & numerical data*
chemical_list: D000701:Analgesics, Opioid; D016568:Drugs, Generic; D002047:Buprenorphine